Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts

Allergy and Asthma Proceedings

Volumn 31, Issue 3, 2010, Pages

  Brehler, Randolf ^a   Klimek, Ludger ^b   Pfaar, Oliver ^b   Hauswald, Bettina ^c   Worm, Margitta ^d   Bieber, Thomas ^e  

^a UKM   (Germany)

^b Center for Rhinology and Allergy   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Allergoid; Allergy; Conjunctivitis; Depigmented extracts; Immunotherapy; Rhinitis; Safety

Indexed keywords

ALLERGEN; DEPIGOID; HOUSE DUST ALLERGEN; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANXIETY; ARTICLE; BRONCHUS OBSTRUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; FEMALE; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLLEN ALLERGY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SENSITIZATION; SIDE EFFECT; SKIN REDNESS; SUBCUTANEOUS IMMUNOTHERAPY; TENESMUS; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADOLESCENT; ADULT; ALLERGENS; CLINICAL PROTOCOLS; COMPLEX MIXTURES; CONJUNCTIVITIS; FEMALE; GLUTARAL; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 77953798672     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3334     Document Type: Article

References (44)

1. Bauchau V, and Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24:758-764, 2004. (Pubitemid 39504428)
2. Heinrich J, Hoelscher B, Frye C, et al. Trends in prevalence of atopic diseases and allergic sensitization in children in Eastern Germany. Eur Respir J 19:1040-1046, 2002. (Pubitemid 34649616)
3. Bousquet J, Lockey R, and Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. WHO Position Paper. Allergy 53(suppl):1-42, 1998.
4. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 24:CD001936, 2007.
5. Cohn JR, and Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 91:734-737, 1993. (Pubitemid 23110718)
6. Lower T, Henry J, Mandik L, et al. Compliance with allergen immunotherapy. Ann Allergy 70:480-482, 1993.
7. Harvey SM, Laurie S, Hilton K, and Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 92:414-419, 2004. (Pubitemid 39077582)
8. Cox L. Accelerated immunotherapy schedules: Review of efficacy and safety. Ann Allergy Asthma Immunol 97:126-137, 2006. (Pubitemid 44272576)
9. Smits W, Inglefield JT, Letz K, et al. Improved immunotherapy with a rapid allergen vaccination schedule: A study of 137 patients. Ear Nose Throat J 82:881-887, 2003. (Pubitemid 37433268)
10. Sharkey P, and Portnoy J. Rush immunotherapy: Experience with a one-day schedule. Ann Allergy Asthma Immunol 76: 175-180, 1996.
11. Finegold I. Allergen immunotherapy: Present and future. Allergy Asthma Proc 28:44-49, 2007.
12. Smits WL, Giese JK, Letz KL, et al. Safety of rush immunotherapy using a modified schedule: A cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc 28:305-312, 2007.
13. Berrens L. International Patent Application PCT. Number of Publication WO 94/06821, 1994.
14. Fernández-Caldas E, Guerra F, Casanovas M, and Gallego M. T-Cell proliferation studies with a depigmented, polymerized extract of Phleum pratense. Allergy 57:65, 2002.
15. Fernández-Caldas E, Carnés J, Iraola V, and Casanovas M. Comparison of the allergenicity and Ole e 1 content of 6 varieties of Olea europaea pollen collected during 5 consecutive years. Ann Allergy Asthma Immunol 98:464-470, 2007. (Pubitemid 46752640)
16. Casanovas M, Góomez MJ, Carnés J, and Fernández- Caldas E. Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts. J Investig Allergol Clin Immunol 15:30-36, 2005.
17. (Erratum in J Investig Allergol Clin Immunol.15: 233, 2005.)
18. Carnés J, Himly M, Gallego M, et al. Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba. Clin Exp Allergy 39:426-434, 2009.
19. García-Robaina JC, Sánchez I, de la Torre F, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 118:1026-1032, 2006. (Pubitemid 44666986)
20. Ameal A, Vega-Chicote JM, Fernández S, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 60:1178-1183, 2005.
21. Colás C, Monzón S, Venturini M, and Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 117:810-816, 2006. (Pubitemid 44313815)
22. Álvarez-Cuesta E, Aragoneses-Gilsanz E, Martín- García C, et al. Immunotherapy with depigmented glutaraldehyde polymerized extracts: changes in quality of life. Clin Exp Allergy 35: 572-578, 2005.
23. (Erratum in Clin Exp Allergy 35:1504, 2005.)
24. Branco Ferreira M, Spinola Santos A, Pereira Santos MC, et al. Efficacy and safety of specific immunotherapy with a modified mite extract. Allergol Immunopathol (Madr) 33:80-85, 2005.
25. Ferrer A, and Garcia-Sellés J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Investig Allergol Clin Immunol 13:244-251, 2003. (Pubitemid 38160367)
26. Casanovas M, Sastre J, Fernández-Nieto M, et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 35:1377-1383, 2005.
27. (Erratum in Clin Exp Allergy 35:1651-1652, 2005.)
28. Malet A, Lluch M, Valero AL, and Casanovas M. Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Allergol Immunopathol (Madr) 22:226-232, 1994.
29. Casanovas M, Martín R, Jiménez C, et al. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 139:153-158, 2006. (Pubitemid 43177328)
30. Casanovas M, Ruiz A, Gómez MJ, et al. Skin testing with native, depigmented and glutaraldehyde polymerized allergen extracts of Dermatophagoides pteronyssinus. J Allergy Clin Immunol 107: 260, 2001.
31. Boluda L, Sastre J, Casanovas M, and Fernández-Caldas E. Determination of Ole e 1 by enzyme immunoassay and scanning densitometry. Validation by skin-prick testing. J Immunol Methods 223:17-26, 1999. (Pubitemid 29096235)
32. Kleine-Tebbe J, Fuchs T, Klimek L, et al. Die spezifische immuntherapie (hyposensibilisierung) mit allergenen. Positions papier des DGAI, inhaltlich abgestimmt mit dem ÄDA. Allergo J 9:317-324, 2000.
33. Goodman DC. When an asthma drug has an inferiority complex: A noninferiority trial. Pediatrics 116:493-495, 2005.
34. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics 116:360-369, 2005.
35. (Erratum in Pediatrics 116:1058, 2005.)
36. Lange S, and Freitag G. Choice of delta: Requirements and reality - Results of a systematic review. Biom J 47:12-27, 2005. (Pubitemid 40390435)
37. Piaggio G, Elbourne DR, Altman DG, et al.; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295:1152-1160, 2006.
38. Kaul S, and Diamond GA. Good enough: A primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 145:62-69, 2006. (Pubitemid 46780603)
39. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 3:345-353, 1982.
40. Frew AJ, Powell RJ, Corrigan CJ, and Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117:319-325, 2006.
41. Nelson HS. Allergen immunotherapy: Where is it now? J Allergy Clin Immunol 119:769-777, 2007.
42. Casale TB, Busse WW, Kline JN, et al.; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134-140, 2006.
43. Sager A, Braeutigam M, Badorrek P, and Krug N. Efficacy of a rush immunotherapy with a depigmented polymerized extract of grass pollen using an environmental challenge chamber. J Allergy Clin Immunol 121:125, 2008.
44. Biller H, Badorrek P, Hohlfeld JM, et al. Efficacy of a rush immunotherapy with a depigmented polymerized extract of grass pollen assessed in an environmental challenge chamber. Allergy 64 (suppl 90):345, 2009.